Precision Medicine: Treating Your Cancer Based on Its DNA...

Innovation & Technology · 2 · February 9, 2026

In 2017, pembrolizumab (Keytruda) became the first cancer drug approved based on a genetic biomarker rather than tumor location — treating any solid tumor with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR). This tissue-agnostic approach has fundamentally changed oncology.

From Tumor Site to Tumor Profile

Traditional oncology: 'You have lung cancer, here's the lung cancer protocol.' Precision oncology: 'Your tumor has an ALK fusion — here's the ALK inhibitor that works regardless of where the tumor is located.' Comprehensive genomic profiling (FoundationOne CDx, Tempus xT, Guardant360) sequences 300-600 cancer-relevant genes from a biopsy sample, identifying actionable mutations in 30-40% of advanced cancer cases — mutations that match approved targeted therapies.

The Biomarker-Drug Matchmaking System

Actionable mutations and their matched therapies: EGFR mutations → osimertinib (Tagrisso). ALK rearrangements → alectinib (Alecensa). BRAF V600E → dabrafenib + trametinib. HER2 amplification → trastuzumab (Herceptin). NTRK fusions → larotrectinib (Vitrakvi). RET fusions → selpercatinib (Retevmo). ROS1 rearrangements → crizotinib (Xalkori).

Each targeted therapy achieves response rates of 50-80% in biomarker-positive patients — far exceeding the 20-30% response rates of untargeted chemotherapy. The difference isn't incremental; it's transformative.

Accessing Precision Oncology Abroad

Genomic profiling costs $3,000-$5,000 per test in the US (often covered by insurance). In India: $800-$1,500 at Tata Memorial, HCG, and MedGenome labs. Turnaround: 2-3 weeks. Once actionable mutations are identified, many targeted therapies are available as generics or biosimilars in India at 70-90% below US pricing. A complete precision oncology workup and 12-month targeted therapy course can cost $10,000-$30,000 in India versus $100,000-$300,000 in the US.

Key Takeaways

- Genomic profiling identifies actionable mutations in 30-40% of advanced cancers

- Targeted therapies achieve 50-80% response rates vs 20-30% for untargeted chemo

- Genomic profiling costs $800-$1,500 in India vs $3,000-$5,000 in the US

- Complete precision oncology (testing + 12-month therapy) costs $10,000-$30,000 in India vs $100,000-$300,000 in the US

Compare real-time pricing using our global cost calculator.